ArsenalBio: Funding, Investors & Team (Oct 2026)
ArsenalBio, established in 2019, is dedicated to developing immune cell therapies that are both highly efficient and widely accessible, particularly for cancer patients. The company is utilizing cutting-edge technologies such as CRISPR-based genome engineering, high throughput target identification, synthetic biology, and machine learning to revolutionize the discovery and development of immune cell therapies. ArsenalBio aims to improve key factors for success in this field, including efficacy, safety, cost-effectiveness, and market availability, through its programmable and data-driven approach.
ArsenalBio has raised $546M across 2 funding rounds on record, the most recent a Series C of $325M announced in Sep 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ArsenalBio Company Profile and Key Stats
Latest funding round on record: Sep 2024.
ArsenalBio Funding Rounds
ArsenalBio raised $221M in a Series B announced in Sep 2022.
2 years later, a Series C of $325M was announced in Sep 2024.
ArsenalBio Founders and Leadership Team
Contact details for the ArsenalBio team: 1 of 1 has an email address on file.
Start 14-day free trial →ArsenalBio Funding Compared to Other Biotechnology Startups
ArsenalBio's latest round of $325M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ArsenalBio in Biotechnology and South San Francisco
Companies Similar to ArsenalBio
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
ArsenalBio Funding FAQs
What does ArsenalBio do?
ArsenalBio, established in 2019, is dedicated to developing immune cell therapies that are both highly efficient and widely accessible, particularly for cancer patients. The company is utilizing cutting-edge technologies such as CRISPR-based genome engineering, high throughput target identification, synthetic biology, and machine learning to revolutionize the discovery and development of immune cell therapies. ArsenalBio aims to improve key factors for success in this field, including efficacy, safety, cost-effectiveness, and market availability, through its programmable and data-driven approach.
How much funding has ArsenalBio raised?
ArsenalBio has raised $546M across 2 rounds on record. The most recent is a Series C of $325M announced in Sep 2024.
When did ArsenalBio last raise funding?
ArsenalBio's most recent funding round on record is a Series C of $325M, announced in Sep 2024.
Who founded ArsenalBio?
FundedIQ lists Ken Drazan (Founder) at ArsenalBio.
Where is ArsenalBio headquartered?
ArsenalBio is based in South San Francisco, California, United States.
How many employees does ArsenalBio have?
ArsenalBio is in the 251-500 employee band.
How does ArsenalBio's funding compare to other Biotechnology startups?
ArsenalBio's latest round of $325M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ArsenalBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ArsenalBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.